Dr. Wise is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
160 East 34th Street
10th Floor
New York, NY 10016Phone+1 212-731-6366Fax+1 212-731-5527- Is this information wrong?
Summary
- My expertise in the management of advanced urologic cancers incorporates the most recently developed imaging and therapeutic modalities and a broad array of targeted and immunotherapy-based clinical trials.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2017
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2011 - 2013
- OtherClass of 2011
- Perelman School of Medicine at the University of PennsylvaniaClass of 2011
Certifications & Licensure
- NY State Medical License 2013 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2022 Jun 27
Roles: Contact
Publications & Presentations
PubMed
- High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy mon...Byun, D., Jonathan W Lischalk, Astrid Sanchez, Vianca F Santos, Christopher Mendez, Meredith Akerman, Todd Carpenter, Moses Tam, David Byun, David R Wise, Anand Mahade...> ;Radiation Oncology. 2024 Mar 4
- TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.Stacy Loeb, Scott W Keith, Heather H Cheng, Amy E Leader, Laura Gross, Tatiana Sanchez Nolasco, Nataliya Byrne, Rebecca Hartman, Lauren H Brown, Christopher Michael Pi...> ;JCO Precision Oncology. 2024 Mar 1
- A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).David R Wise, Russell K Pachynski, Samuel R Denmeade, Rahul R Aggarwal, Jiehui Deng, Victor Adorno Febles, Arjun V Balar, Minas P Economides, Cynthia Loomis, Shanmugap...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 10
- Join now to see all
Press Mentions
- EU Thumbs up for Oral ADT for Prostate CancerFebruary 28th, 2022
- Prospective Study Characterizes PCa Risk Linked to BRCA1, BRCA2 MutationsSeptember 24th, 2019
- European Urologists Release Position Paper on Immune Checkpoint Inhibitor ToxicitiesAugust 2nd, 2019
- Join now to see all
Hospital Affiliations
- NYU Langone HospitalsNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: